AIDX · 20/20 Biolabs, Inc. · Insider Trading

$0.35 -0.03 (-9.16%)

Market Cap

$5.31M

12.77M

Volume · Oct 5 116.67K Avg daily vol (3M) 92.73K

Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.

Query insider transactions through the insider trading API or MCP →

Date	Insider	Role	Type	Security	Shares	Price	Value	After
2026-04-02	Zhou Jiming	Chief Operating Officer	Award↑	Stock Option	150,000	—	—	150,000
2026-04-02	Bergman Alan B.	Chief Financial Officer	Award↑ Filing footnotes — Stock Option (Direct) 25,000 of the shares subject to the stock option will vest on the first anniversary of the date of grant and the remaining shares will vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continuous service to the Issuer.	Stock Option	100,000	—	—	100,000
2026-03-03	Cohen Jonathan M	Director, Chief Executive Officer, 10% Owner	Award↑ Filing footnotes — Stock Option (Direct) On March 3, 2026, the Reporting Person was granted a stock option for the purchase of 352,936 shares of common stock, which shall vest in equal quarterly installments over the following four (4) years, subject to the Reporting Person's continuous service to the Issuer.	Stock Option	352,936	—	—	352,936
2026-02-19	Ross Michael A.	Director	Other↑ Filing footnotes — Common Stock (Direct) On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date.	Common Stock	31	—	—	31
2026-02-19	Ross Michael A.	Director	Other↓ Filing footnotes — Series A-2 Preferred Stock (Direct) On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date.	Series A-2 Preferred Stock	31	—	—	0
2026-02-19	Rollins John Woodson	Director	Other↑ Filing footnotes — Common Stock (Direct) On February 19, 2026, all shares of series A preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A preferred stock had no expiration date.	Common Stock	13,029	—	—	24,140
2026-02-19	Compton John G.	Director	Other↓ Filing footnotes — Series A-2 Preferred Stock (Direct) On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date.	Series A-2 Preferred Stock	7,669	—	—	0
2026-02-19	COHEN RICHARD M	Director	Other↓ Filing footnotes — Series A-2 Preferred Stock (Direct) On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date.	Series A-2 Preferred Stock	7,700	—	—	0
2026-02-19	COHEN RICHARD M	Director	Other↑ Filing footnotes — Common Stock (Direct) On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date.	Common Stock	7,700	—	—	7,700
2026-02-19	Rollins John Woodson	Director	Other↑ Filing footnotes — Common Stock (Direct) On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date.	Common Stock	6,135	—	—	30,275
2026-02-19	Rollins John Woodson	Director	Other↓ Filing footnotes — Series A-2 Preferred Stock (Direct) On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date.	Series A-2 Preferred Stock	6,135	—	—	0
2026-02-19	Rollins John Woodson	Director	Other↓ Filing footnotes — Series A Preferred Stock (Direct) On February 19, 2026, all shares of series A preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A preferred stock had no expiration date.	Series A Preferred Stock	13,029	—	—	0
2026-02-19	Compton John G.	Director	Other↑ Filing footnotes — Common Stock (Direct) On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date.	Common Stock	7,669	—	—	14,335

Legend Buy — open-market purchase Sell — open-market sale ↑ Shares acquired ↓ Shares disposed (gift, conversion, tax…)

Showing 1–13 of 13 transactions

Key facts CIK 1139685 CUSIP 90138K101 Visit website Investor relations